Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 6Genitourinary 2Dermatologic 2Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Melanoma 36Uveal Melanoma 8Brain Neoplasms 4Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Merkel Cell 3Carcinoma, Basal Cell 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Anaplastic 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Immunoblastic Lymphadenopathy 2Gastrointestinal Stromal Tumors 2Waldenstrom Macroglobulinemia 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Somatostatinoma 1Sezary Syndrome 1Seminoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Rare Diseases 1

Interventions

pembrolizumab 22Nivolumab 17Magnetic Resonance Spectroscopy 12Specimen Handling 10Cyclophosphamide 9Radiosurgery 7Drug Therapy 6Radiotherapy 5Paclitaxel 5Ipilimumab 5fludarabine 4Biopsy 4trametinib 3sargramostim 3Trastuzumab 3Taxes 3Pemetrexed 3Metformin 3Interleukin-2 3Immunoglobulin G 3Gemcitabine 3Carboplatin 3Bevacizumab 3tremelimumab 2temsirolimus 2poly ICLC 2pertuzumab 2osimertinib 2motexafin gadolinium 2epacadostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × CTLA-4 Antigen × Dermatologic × Clear all
NCT04940299 2026-03-06

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
35 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Ureteral Neoplasms, Urethral Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡